CARDIOLOGY GRAND ROUNDS

Presentation: Renal Denervation, Second Time is a Charm?

Speaker: Robert S. Schwartz, MD, FACC, FAHA, FSCAI
Senior Consulting Cardiologist, Minneapolis Heart Institute® at Abbott Northwestern Hospital; Medical Director – Professional Education, Minneapolis Heart Institute Foundation

Date: Monday, January 19, 2015, 7:00 – 8:00 AM
Location: ANW Education Building, Watson Room

OBJECTIVES
At the completion of this activity, the participants should be able to:
1. Describe renal denervation physiology and anatomy
2. Describe the Symplicity HTN-3 trial and its potential reasons for failure
3. Explain the importance of patient selection moving forward in renal denervation trials

ACCREDITATION
Physicians: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Allina Health and Minneapolis Heart Institute Foundation. Allina Health is accredited by the ACCME to provide continuing medical education for physicians.

Allina Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses: This activity has been designed to meet the Minnesota Board of Nursing continuing education requirements for 1.2 hours of credit. However, the nurse is responsible for determining whether this activity meets the requirements for acceptable continuing education.

Others: Individuals representing other professional disciplines may submit course materials to their respective professional associations for 1.0 hours of continuing education credit.

DISCLOSURE STATEMENTS
Speaker(s): Robert S. Schwartz, MD has declared the following financial relationships: Boston Scientific research support.

Planning Committee: Dr. Michael Miedema and Eva Zewdie have declared that they do not have any conflicts of interest associated with the planning of this activity. Dr. Robert Schwartz declared the following relationships - stockholder: Cardiomind, Interface Biologics, Aritech, DSI/Transoma, InstyMeds, Intervale, Medtronic, Osprey Medical, Stout Medical, Tricardia LLC, CoAptus Inc, Augustine Biomedical; scientific advisory board: Abbott Laboratories, Boston Scientific, MEDRAD Inc, Thomas, McNerney & Partners, Cardiomind, Interface Biologics; options: BackBeat Medical, BioHeart, CHF Solutions; speakers bureau: Vital Images; consultant: Edwards LifeSciences.